P-Akt expression distinguishes two types of malignant rhabdoid tumors

Journal of Cellular Physiology

Volumn 209, Issue 2, 2006, Pages 422-427

  Charboneau, Aubri ^a,b   Chai, Jingjing ^a,b   Jordan, Jennifer ^b   Funkhouser, William ^a,b   Judkins, Alexander ^c   Biegel, Jaclyn ^c   Weissman, Bernard ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P21;

ARTICLE; CANCER THERAPY; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM; CHILDHOOD CANCER; CONTROLLED STUDY; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; GENE INACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOID TUMOR; SIGNAL TRANSDUCTION; SNF5 GENE; TUMOR CELL LINE; TUMOR CLASSIFICATION; TUMOR SUPPRESSOR GENE;

CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; MUTANT PROTEINS; PHOSPHORYLATION; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RHABDOID TUMOR; TUMOR CELLS, CULTURED;

EID: 33749238894     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20737     Document Type: Article

References (43)

1. Andjelkovic M, Jakubowicz T, Cron P, Ming XF, Han JW, Hemmings BA. 1996. Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proc Natl Acad Sci USA 93(12):5699-5704.
2. Asosingh K, Gunthert U, De Raeve H, Van Riet I, Van Camp B, Vanderkerken K. 2001. A unique pathway in the homing of murine multiple myeloma cells: CD44v10 mediates binding to bone marrow endothelium. Cancer Res 61(7):2862-2865.
3. Betz BL, Strobeck MW, Reisman DN, Knudsen ES, Weissman BE. 2002. Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB. Oncogene 21(34):5193-5203.
4. Biegel JA, Kalpana G, Knudsen ES, Packer RJ, Roberts CW, Thiele CJ, Weissman B, Smith M. 2002. The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors: Meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumors. Cancer Res 62(1):323-328.
5. Brazil DP, Yang ZZ, Hemmings BA. 2004. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 29(5):233-242.
6. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. 1999. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96(6):857-868.
7. Chai J, Charboneau AL, Betz BL, Weissman BE. 2005. Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. Cancer Res 65(22):10192-10198.
8. Chan S. 2004. Targeting the mammalian target of rapamycin (mTOR): A new approach to treating cancer. Br J Cancer 91(8):1420-1424.
9. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK. 2001. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20(42):6073-6083.
10. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. 1997. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278(5338):687-689.
11. Dowdy SF, Fasching CL, Scanlon DJ, Araujo D, Livanos E, Lai K-M, Weissman BE, Stanbridge EJ. 1991. Suppression of tumorigenicity in Wilms' tumor by the p14:p15 region of chromosome 11. Science 254:293-295.
12. Fichter M, Hinrichs R, Eissner G, Scheffer B, Classen S, Ueffing M. 1997. Expression of CD44 isoforms in neuroblastoma cells is regulated by PI 3-kinase and protein kinase C. Oncogene 14(23):2817-2824.
13. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. 2003. PI3K/Akt and apoptosis: Size matters. Oncogene 22(56):8983-8998.
14. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. 2004. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30(2):193-204.
15. Guidi CJ, Sands AT, Zambrowicz BP, Turner TK, Demers DA, Webster W, Smith TW, Imbalzano AN, Jones SN. 2001. Disruption of ini1 leads to peri-implantation lethality and tumorigenesis in mice. Mol Cell Biol 21(10):3598-3603.
16. Hanada M, Feng J, Hemmings BA. 2004. Structure, regulation and function of PKB/AKT - A major therapeutic target. Biochim Biophys Acta 1697(1-2):3-16.
17. Hebbard L, Steffen A, Zawadzki V, Fieber C, Howells N, Moll J, Ponta H, Hofmann M, Sleeman J. 2000. CD44 expression and regulation during mammary gland development and function. J Cell Sci 113(Pt 14):2619-2630.
18. Hoot AC, Russo P, Judkins AR, Perlman EJ, Biegel JA. 2004. Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors. Am J Surg Pathol 28(11):1485-1491.
19. Hu X, Pandolfi PP, Li Y, Koutcher JA, Rosenblum M, Holland EC. 2005. mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia 7(4):356-368.
20. Isakoff MS, Sansam CG, Tamayo P, Subramanian A, Evans JA, Fillmore CM, Wang X, Biegel JA, Pomeroy SL, Mesirov JP, Roberts CW. 2005. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci USA 102(49):17745-17750.
21. Klochendler-Yeivin A, Fiette L, Barra J, Muchardt C, Babinet C, Yaniv M. 2000. The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression. EMBO Rep 1(6):500-506.
22. Klochendler-Yeivin A, Picarsky E, Yaniv M. 2006. Increased DNA damage sensitivity and apoptosis in cells lacking the Snf5/Ini1 subunit of the SWI/SNF chromatin remodeling complex. Mol Cell Biol 26(7):2661-2674.
23. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275(5308):1943-1947.
24. Liang J, Slingerland JM. 2003. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2(4):339-345.
25. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM. 2002. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 8(10):1153-1160.
26. MacDonald TJ, Rood BR, Santi MR, Vezina G, Bingaman K, Cogen PH, Packer RJ. 2003. Advances in the diagnosis, molecular genetics, and treatment of pediatric embryonal CNS tumors. Oncologist 8(2):174-186.
27. Maehama T, Dixon JE. 1998. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273(22):13375-13378.
28. Nocentini S. 2003. Apoptotic response of malignant rhabdoid tumor cells. Cancer Cell Int 3(1):11.
29. Oruetxebarria I, Venturini F, Kekarainen T, Houweling A, Zuijderduijn LM, Mohd-Sarip A, Vries RG, Hoeben RC, Verrijzer CP. 2004. P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells. J Biol Chem 279(5):3807-3816.
30. Reddy AT. 2005. Atypical teratoid/rhabdoid tumors of the central nervous system. J Neurooncol 75(3):309-313.
31. Reincke BS, Rosson GB, Oswald BW, Wright CF. 2003. INI1 expression induces cell cycle arrest and markers of senescence in malignant rhabdoid tumor cells. J Cell Physiol 194(3):303-313.
32. Roberts CW, Galusha SA, McMenamin ME, Fletcher CD, Orkin SH. 2000. Haploinsufficiency of snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc Natl Acad Sci USA 97(25):13796-13800.
33. Ronghe MD, Moss TH, Lowis SP. 2004. Treatment of CNS malignant rhabdoid tumors. Pediatr Blood Cancer 42(3):254-260.
34. Scheid MP, Woodgett JR. 2003. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett 546(1):108-112.
35. Sinor AD, Lillien L. 2004. Akt-1 expression level regulates CNS precursors. J Neurosci 24(39):8531-8541.
36. Sugimoto T, Hosoi H, Horii Y, Ishida H, Mine H, Takahashi K, Abe T, Ohta S, Sawada T. 1999. Malignant rhabdoid-tumor cell line showing neural and smooth-muscle-cell phenotypes. Int J Cancer 82(5):678-686.
37. Tanaka Y, Gavrielides MV, Mitsuuchi Y, Fujii T, Kazanietz MG. 2003. Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem 278(36):33753-33762.
38. Thompson JE, Thompson CB. 2004. Putting the rap on Akt. J Clin Oncol 22(20):4217-4226.
39. Versteege I, Medjkane S, Rouillard D, Delattre O. 2002. A key role of the hSNF5/INI1 tumour suppressor in the control of the G1-S transition of the cell cycle. Oncogene 21(42):6403-6412.
40. Wang Q, Wang X, Hernandez A, Hellmich MR, Gatalica Z, Evers BM. 2002. Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells. J Biol Chem 277(39):36602-36610.
41. Yang ZZ, Tschopp O, Baudry A, Dummler B, Hynx D, Hemmings BA. 2004. Physiological functions of protein kinase B/Akt. Biochem Soc Trans 32(Pt 2):350-354.
42. Yoshida S, Narita T, Koshida S, Ohta S, Takeuchi Y. 2003. TRAIL/Apo2L ligands induce apoptosis in malignant rhabdoid tumor cell lines. Pediatr Res 54(5):709-717.
43. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. 2001. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 3(3):245-252.